Back to Journals » OncoTargets and Therapy » Volume 15

Emodin Suppresses Proliferation, Migration and Invasion in Ovarian Cancer Cells by down Regulating ILK in vitro and in vivo [Retraction]

Authors Lu JJ, Xu Y, Zhao Z, Ke XN, Wei X, Kang J, Zong X, Mao HL, Liu PS 

Received 8 August 2022

Accepted for publication 8 August 2022

Published 10 August 2022 Volume 2022:15 Pages 851—852

DOI https://doi.org/10.2147/OTT.S385443



Lu JJ, Xu Y, Zhao Z, et al. Onco Targets Ther. 2017;10:3579–3589.

At the authors request, the Editor and Publisher of OncoTargets and Therapy wish to retract the published article. The authors raised concerns after discovering the duplication of cell migration and invasion images in Figures 1 and 2. Specifically,

  • Figure 1E, A2780, Migration, Normal appears to have been duplicated with Figure 1E, A2780, Migration pLVX-Con.
  • Figure 1E, SK-OV-3, Invasion, Normal appears to have been duplicated with Figure 2C, SK-OV-3, Invasion, pLVX-Con+, pLVX-ILK-, Emodin-.

The authors provided original data and requested to retract the article. All the authors agreed that the retraction was necessary for reasons of scientific accuracy. The Editor agreed with this decision.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.